Loading
Cancer Survivorship and Care / Thyroid Cancer Diagnosis and Treatment / Advances in Oncology and Radiotherapy · Journal article
Thyroid · August 11, 2026
Encouraging direction, but not yet definitive.
The TC-MAX is a newly developed 18-item self-report scale measuring thyroid cancer-related anxiety across three subscales, validated in 1,002 papillary thyroid cancer patients. The instrument demonstrates strong internal consistency, test–retest reliability, and construct validity against established distress measures, with clinically meaningful severity categories and minimal clinically important differences identified for treatment decision contexts.
Instrument development and external validation study with internal and external cohorts. Papillary thyroid cancer patients enrolled for internal validation (n=148) and external validation (n=1,002). Development phase also included expert panelists and patient focus groups.. Intervention: TC-MAX 18-item self-report scale encompassing three subscales: Collective Anxiety, Ultrasound Anxiety, and Fear of Recurrence/Progression. Compared with: Construct validity assessed against Distress Thermometer, Hospital Anxiety Depression Scale (HADS), and Functional Assessment of Cancer Therapy-General (FACT-G); anchor-based MCID compared active surveillance vs. surgery and hemithyroidect…. n = 1,002.
Internal consistency (Cronbach's α) was 0.93 in internal validation cohort and 0.94 in external validation cohort Test–retest reliability (ICC) was 0.86 in internal validation and 0.87 in external validation Construct validity confirmed via significant correlations with Distress Thermometer (ρ = 0.56 internal, ρ = 0.54 external), HADS (ρ = 0.52 internal, ρ = 0.67 external), and FACT-G (ρ = −0.50 internal, ρ = −0.62 external), all p < 0.001
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians can use TC-MAX to systematically measure and track patient anxiety in thyroid cancer, potentially improving recognition of distress that influences treatment decisions. The scale provides objective severity categories and can help identify patients who may benefit from active surveillance versus surgery based on anxiety levels.
Sound instrument development and validation study with robust psychometrics in a relevant population, but measures a patient-reported outcome (anxiety) rather than a clinical endpoint, and is limited to papillary thyroid cancer patients.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians can use TC-MAX to systematically measure and track patient anxiety in thyroid cancer, potentially improving recognition of distress that influences treatment decisions. The scale provides objective severity categories and can help identify patients who may benefit from active surveillance versus surgery based on anxiety levels.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Patient distress associated with thyroid cancer greatly influences treatment choice, yet is underestimated by clinicians. We developed and validated the Thyroid Cancer Modified Anxiety Scale (TC-MAX) to measure patient-reported thyroid cancer-related worry. Methods: Development entailed (1) conceptualization (systematic literature review, expert panel [ n = 4], patient focus groups [ n = 10]); (2) qualitative revision (pilot testing [ n = 59], expert panel [ n = 4], patient feedback [ n = 4]); (3) internal validation ( n = 148); and (4) external validation ( n = 1002), with papillary thyroid cancer patients. Internal consistency, test–retest reliability, exploratory/confirmatory factor analysis, and construct validity were evaluated. Severity categories and minimal clinically important differences (MCIDs) were determined. Results: An 18-question scale was constructed, encompassing three subscales (Collective Anxiety, Ultrasound Anxiety, and Fear of Recurrence/Progression). Internal validation revealed high internal consistency (Cronbach’s α = 0.93), excellent test–retest reliability (intraclass correlation coefficient [ICC] 0.86), and significant construct validity (Distress Thermometer [Spearman’s ρ = 0.56, p < 0.001], Hospital Anxiety Depression Scale [HADS] [Spearman’s ρ = 0.52, p < 0.001], and Functional Assessment of Cancer Therapy-General [FACT-G] [Spearman’s ρ = −0.50, p < 0.001]). Exploratory factor analysis showed expected loadings for respective subscales, and confirmatory factor analysis confirmed that the structure was parsimonious. External validation exhibited similar psychometrics, including internal consistency (Cronbach’s α = 0.94), test–retest reliability (ICC 0.87), and construct validity (Distress Thermometer [Spearman’s ρ = 0.54, p < 0.001], HADS [Spearman’s ρ = 0.67, p < 0.001], and FACT-G [Spearman’s ρ = −0.62, p < 0.001]). Proposed ranges (low = 0–26, moderate = 26–43, and severe = 43–100) were in excellent agreement between internal and external validation cohorts (weighted κ = 0.84, p < 0.001). Anchor-based MCID was found to be 16.7 (active surveillance vs. surgery) (25.9 [standard deviation (SD) ± 16.4] vs. 42.6 [SD ± 23.3], p < 0.001) or 16.9 (hemithyroidectomy vs. thyroidectomy) (33.6 [SD ± 17.4] vs. 50.5 [SD ± 24.1], p = 0.005). Conclusions: TC-MAX represents the first dedicated measure of anxiety in thyroid cancer. It exhibits robust psychometric properties in a vulnerable population, accounting for complex viewpoints. The scale effectively assesses preference and informs patients, including determining fit for active surveillance or extent of surgery.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.